Video Experimental Relacionado
Updated: Feb 21, 2026
04:48
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
7.8K
Toxicidad cardiovascular relacionada con la inmunoterapia: de los mecanismos al manejo
Lifeng Xiao1, Weitong Liu2, Yanchen Ji3
1Department of Emergency, Cancer Hospital of Shantou University Medical College, Shantou, China.
Frontiers in pharmacology
|February 20, 2026
Resumen
Las inmunoterapias contra el cáncer como los inhibidores de los puntos de control y las células CAR-T pueden causar problemas cardíacos. Esta revisión cubre sus toxicidades cardiovasculares, mecanismos y estrategias de manejo para mejores resultados para los pacientes.
Área de la Ciencia:
- Cardio-oncología.
- Los eventos adversos de la inmunoterapia son eventos adversos de la inmunoterapia.
Sus antecedentes:
- Las inmunoterapias contra el cáncer han transformado el tratamiento oncológico.
- Las toxicidades cardiovasculares son una preocupación significativa con estas terapias.
Objetivo del estudio:
- Revisar las toxicidades cardiovasculares asociadas con la inmunoterapia contra el cáncer.
- Explorar los mecanismos, la estratificación del riesgo, el monitoreo y la gestión.
- Para discutir las direcciones futuras en la cardio-oncología.
Principales métodos:
- Revisión exhaustiva de la literatura sobre los eventos adversos cardiovasculares.
- Análisis de los mecanismos fisiopatológicos.
- Evaluación de las estrategias actuales de gestión y monitoreo.
Principales resultados:
- Las toxicidades cardiovasculares relacionadas con la inmunoterapia incluyen miocarditis, enfermedad pericárdica, arritmias e insuficiencia cardíaca.
- Los mecanismos implican la reactividad cruzada de las células T y el síndrome de liberación de citoquinas.
- La gestión eficaz requiere la estratificación de riesgos, el monitoreo y el cuidado multidisciplinario.
Conclusiones:
- Un enfoque proactivo de la cardio-oncología es esencial.
- La mitigación de los riesgos cardiovasculares es crucial para el uso seguro de la inmunoterapia.
- La investigación futura debe centrarse en nuevos objetivos y monitoreo avanzado.
Palabras clave:
Cardio-oncología de la cardiología.cardiotoxicidad y cardiotoxicidad.Síndrome de liberación de citoquinas.La insuficiencia cardíaca es insuficiencia cardíaca.inhibidores del punto de control inmune inhibidores del punto de control inmuneeventos adversos relacionados con el sistema inmunológico.La miocarditis es una miocarditis.Más Videos Relacionados
Videos de Conceptos Relacionados
01:14Myocarditis III: Medical Management
238
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
238
01:27Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
01:22Myocarditis IV: Nursing Management
277
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
277
01:17Pericarditis III: Medical Management
404
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
404
01:29Cardiomyopathy V: Interprofessional Care
501
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
501
01:26Heart Failure Drugs: Inotropic Agents
1.6K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.6K